Table 1 Socio-demographic and biomarkers data of controls and Long COVID (LC) patients divided into two groups one with highly increased body temperature, lowered SpO2 and high nitro-oxidative stress (LC + O&NS) versus another group with fewer changes in these biomarkers (LC).
Variables | Controls (n = 36)A | Cluster 1 or LC (n = 67)B | Cluster 2: LC + O&NS (n = 51)C | F/ψ/χ2 | df | p |
|---|---|---|---|---|---|---|
Age (years) | 30.9 ± 8.3 | 29.3 ± 7.2 | 33.1 ± 8.6 | 3.32 | 2/151 | 0.039 |
BMI (kg/m2) | 26.34 ± 3.64 | 25.60 ± 3.97 | 26.65 ± 6.20 | 0.72 | 2/146 | 0.487 |
Sex (Female/Male) | 6/30 | 25/42 | 8/43 | 9.02 | 2 | 0.012 |
Education (years) | 15.8 ± 1.2C | 15.6 ± 1.6C | 15.5 ± 1.8A,B | 0.37 | 2/151 | 0.689 |
Single/married | 22/14 | 34/33 | 15/36 | 9.56 | 2 | 0.008 |
TUD (No/Yes) | 20/16 | 45/22 | 36/15 | 2.24 | 2 | 0.321 |
Residency (Urban/Rural) | 7/29 | 7/60 | 12/39 | 3.75 | 2 | 0.166 |
Employment (No/Yes) | 36 | 67 | 51 | – | – | – |
Vaccination (A/Pf/S) | 11/14/11 | 23/30/14 | 20/19/12 | 1.83 | 4 | 0.768 |
Duration of Disease (weeks) | – | 13.8 ± 3.7C | 15.8 ± 6.8B | 4.16 | 1/116 | 0.044 |
Peak body temperature (°C) | 36.5 ± 0.1B,C | 38.8 ± .0.1A,C | 39.3 ± 0.1A,B | 163.99 | 2/142 | <0.001 |
Lowest SpO2 (%) | 96.6 ± 0.6B,C | 92.3 ± 0.4A,C | 87.5 ± 0.5A,B | 70.06 | 2/142 | <0.001 |
zTO2 index (z scores) | −1.340 ± 0.091B,C | 0.143 ± 0.070A,C | 0.862 ± 0.079A,B | 170.24 | 2/142 | <0.001 |
Gpx (ng/ml) | 23.46 ± 0.97B,C | 21.57 ± 0.75A,C | 17.97 ± 0.84A,B | 9.84 | 2/142 | <0.001 |
NO (uM) | 20.81 ± 1.47C | 18.95 ± 1.13C | 28.19 ± 1.27A,B | 14.99 | 2/142 | <0.001 |
Protein carbonyl (ng/ml) | 11.38 ± 1.15C | 10.73 ± 0.89C | 14.43 ± 1.00A,B | 3.97 | 2/142 | 0.021 |
MPO (ng/ml) | 12.87 ± 0.82C | 11.25 ± 0.63C | 15.84 ± 0.71A,B | 11.32 | 2/142 | <0.001 |
MDA (nM) | 1406.9 ± 97.9C | 1432.9 ± 75.5C | 1843.0 ± 84.6A,B | 8.02 | 2/142 | <0.001 |
AOPP (uM) | 4.84 ± 0.38 | 5.27 ± 0.29 | 5.87 ± 0.33 | 2.19 | 2/142 | 0.116 |
TAC (U/ml) | 6.23 ± 0.48 | 5.23 ± 0.37 | 5.01 ± 0.41 | 2.09 | 2/142 | 0.128 |
Nitrotyrosine (nM) | 33.44 ± 3.20 | 34.79 ± 2.46 | 32.72 ± 2.76 | 0.16 | 2/142 | 0.865 |
Zinc (ppm) | 0.785 ± 0.034C | 0.772 ± 0.026C | 0.657 ± 0.030A,B | 5.37 | 2/142 | 0.006 |
OSTOX (z scores) | −0.357 ± 0.131C | −0.512 ± 0.101C | 0.882 ± 0.113A,B | 45.19 | 2/142 | <0.001 |
ANTIOX (z scores) | 0.521 ± 0.151B,C | 0.107 ± 0.116A,C | −0.580 ± 0.130A,B | 16.17 | 2/142 | <0.001 |
OSTOX / ANTIOX (z scores) | −0.575 ± 0.129A | −0.406 ± 0.100A | 0.957 ± 0.113A,B | 53.62 | 2/142 | <0.001 |
CRP (mg/L) | 5.42 (0.70)B,C | 7.83 (0.55)A | 9.11 (0.61)A | 7.96 | 2/140 | <0.001 |
Enoxaparin sodium (No/Yes)a | 61/6 | 38/13 | 5.86 | 1 | 0.015 | |
Dexamethasone (No/Yes)a | 54/13 | 27/24 | 10.29 | 1 | 0.001 | |
Ceftriaxone (No/Yes)a | 51/16 | 34/17 | 1.28 | 1 | 0.257 | |
Azithromycine (No/Yes)a | 31/36 | 25/26 | 0.09 | 1 | 0.767 | |
Bromhexine (No/Yes)a | 50/17 | 26/25 | 7.06 | 1 | 0.008 | |
Levoflaxacin (No/Yes)a | 61/6 | 41/10 | 2.80 | 1 | 0.094 | |
Antidepressants (No/Yes)b | 55/12 | 35/16 | 2.90 | 1 | 0.089 | |
Chlordiazepoxide (No/Yes)b | 65/2 | 45/6 | FEPT | 1 | 0.059 | |
Propanolol (No/Yes)b | 63/4 | 49/2 | 0.25 | 1 | 0.616 |